Asad Haider
Stock Analyst at Goldman Sachs
(2.46)
# 2,479
Out of 5,005 analysts
10
Total ratings
100%
Success rate
9.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INVA Innoviva | Initiates: Sell | $17 | $17.48 | -2.75% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $36.07 | +16.44% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $42.66 | -10.92% | 1 | Sep 12, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Neutral | $27 | $30.67 | -11.97% | 1 | Jul 17, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $105.49 | +4.28% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $188.64 | -8.82% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $839.87 | +5.73% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $233.91 | -17.06% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $45.45 | +21.01% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $27.37 | -8.66% | 1 | Apr 8, 2025 |
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $17.48
Upside: -2.75%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $36.07
Upside: +16.44%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $42.66
Upside: -10.92%
NewAmsterdam Pharma Company
Jul 17, 2025
Initiates: Neutral
Price Target: $27
Current: $30.67
Upside: -11.97%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $105.49
Upside: +4.28%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $188.64
Upside: -8.82%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $839.87
Upside: +5.73%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $233.91
Upside: -17.06%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $45.45
Upside: +21.01%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $27.37
Upside: -8.66%